People - Directors

Our Board of Directors believes that the purpose of corporate governance is to ensure that stockholder value is maximized in a manner consistent with the strategic plans for our company, legal requirements, the highest standards of integrity, and other standards. Our Board adheres to corporate governance practices which the Board and senior management believe promote this purpose and are sound. The Board is comprised of 7 voting members. Currently there is 1 vacancy.

Board of Directors:

R. Gary Mesch Chairman, CEO, MicroPhage, Inc.

Mr. R. Gary Mesch has been the Chairman of MicroPhage as of June 2007. Mr. Mesch comes to MicroPhage as the current managing director of Alpine Angels, a Vail Valley-based angel investment group that organizes financing for and advises start-up technology companies. Mr Mesch is also an active director of several start-up companies funded through Alpine Angels members. Mr. Mesch has been the founder and Managing Director of several successful data and telecom companies operating in the U.S. and Europe and has been instrumental in launching several other start-up enterprises. Mr. Mesch founded VersaTel telecom in 1995 in Amsterdam and served as CEO and then Chairman until 2002. VersaTel grew to become the second facilities based telecom operator throughout The Netherlands, Belgium, and Germany. In 2005 Versatel was purchased by Tele2 of Sweden and Apax Partners for $1.5 billion. Previous to VersaTel, Mr. Mesch as Managing Director of Open Skies, Inc., a telecom consulting company based in Amsterdam, advised European telecom operators on launching innovative services. From 1984 to 1990 he was co-founder of Nova-Net communications, Inc. a Denver-based nationwide data network provider that was sold to ICG, a Denver-based CLEC telecom company. Mr Mesch holds a B.S. in Electrical Engineering from the University of Colorado and an MBA from the University of Denver.

Larry Gold, Ph.D. Director, Scientific Advisory Board Chairman. Chairman and Chief Scientific Officer, SomaLogic, Inc (Boulder CO)

Dr. Gold is the founder of SomaLogic, Inc of Boulder CO. He was also the founder of NeXagen, which later became NeXstar Pharmaceuticals, Inc. Dr. Gold was a director at NeXstar from its inception in 1991 and was Chairman of the Board from February 1993 until July 1999. He was Executive Vice President of Research and Development of NeXstar from March 1991 to February 1995. In February 1995, he was named Chief Scientific Officer of NeXstar. From January 1981 to June 1988, Dr. Gold served as Co-Director of Research for Synergen, Inc. Dr. Gold was also a founder of Synergen. Dr. Gold has been a professor at the University of Colorado at Boulder (CU) since 1970. From 1988 to 1992, he also served as Chairman of the Department of Molecular, Cellular and Developmental Biology where he received the CU Distinguished Lectureship Award. While maintaining his affiliation with CU, Dr. Gold now has only minimal responsibilities at the university. Dr. Gold received the National Institutes of Health Merit Award and the Career Development Award and was awarded the Chiron prize for Biotechnology in 1995. Dr. Gold has been a member of the National Academy of Sciences since 1995 and the American Academy of Arts and Sciences since 1993. Dr. Gold is also a member of MicroPhage’s Scientific Advisory Board and Bacteriophage Advisory Board.

Stephen K. Onody Director. Managing Director – Onody and Associates (Aurora CO)

Mr. Onody was previously the Chief Executive Officer and President of Lifeline Therapeutics and brings 28 years of experience in healthcare companies, most recently serving as Chairman and CEO of Colorado MEDtech (CMED), a publicly-traded NASDAQ company in Denver. He previously served in senior management roles at Boston Scientific Corporation, SpaceLabs Medical, and Vital Signs, Inc. Mr. Onody has been the recipient of several entrepreneurial and leadership awards while serving as Chairman and CEO of Colorado MEDtech, including Entrepreneur of the Year, Ernst & Young-sponsored Finalist 2002; Denver Post Top-100 Performing Public Companies, four (4) consecutive years; Deloitte & Touche Colorado Technology Fast 50 Award, four (4) consecutive years; and Fortune Magazine 100 fastest Growing Companies, 2001.

Photios "Fred" Paulson, MS Director. Former Chairman, bioMerieux Vitek, Inc.

Mr. Paulson has a proven track record with over 40 years of experience in the healthcare industry having held senior management positions at leading medical devices companies as well as in the healthcare investment banking field. Mr. Paulson began his career at Becton Dickinson, a NYSE-traded company engaged in the manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products, where he served for over 25 years in various capacities, and was ultimately appointed as executive vice president and chief operating officer. More recently, Mr. Paulson served as Chairman of bioMerieux Vitek Inc., an internationally recognized company that develops, manufactures and markets reagents and automated instruments used for in vitro infectious disease diagnostics. Prior to this, Mr. Paulson spent 3 years as a senior advisor, healthcare and international investment banking with Prudential Securities. Mr. Paulson has served as a director of numerous healthcare companies over the past 10 years. He is a graduate of the Advanced Management Program at Harvard University, and holds an MS in Industrial Management and a BS in Mechanical Engineering, both from Stevens Institute of Technology.

Mark Schwartz, MD, JD Director. Founding Partner, Shelist and Schwartz, LLP.

Dr. Schwartz received his undergraduate degree in 1983 from Cornell University, majoring in immunology and genetics. Thereafter, he obtained both his Medical Doctorate (University of Illinois College of Medicine, Alpha Omega Alpha Medical Honorary Society, 1988) and Juris Doctorate (John Marshall Law School, magna cum laude, 1994) in Chicago, Illinois. Currently, Dr. Schwartz is a member of Alpine Angels, a Colorado-based private equity group, and is a practicing attorney with several offices nationwide. Dr. Schwartz serves on a number of boards and is a consultant and advisor to numerous start-up companies.

John H. Wheeler Director. Founder, Vice President - Business Development MicroPhage, Inc.

Mr. Wheeler brings 30 years of business experience in the biomedical and diagnostics fields to the Company. Prior to founding MicroPhage Incorporated™ , Mr. Wheeler founded Xtrana, Inc.(NASDAQ:XTRN) as its President and CEO, a molecular diagnostics company specializing in nucleic acid extraction and detection. Previous to Xtrana, he served as Vice President of Sales, Marketing and Business Development at Xenometrix, Inc. a molecular toxicology company, from 1993 to 1997. From 1992 to 1993, Mr. Wheeler was Director of Sales and Marketing for Research Biochemicals, Ltd. and from 1987 to 1992, Mr. Wheeler was employed by Charles River Laboratories where he held positions including Director of Operations and Vice President of Sales and Marketing. Prior to 1987, he held positions in sales, marketing and strategic business planning both in the United States and Europe with Becton Dickinson Company. Mr. Wheeler received his M.B.A. from Pace University, New York in 1986 and his B.A. in biology from the University of Bridgeport in 1970. Mr. Wheeler currently serves as the Chair of the Colorado BioScience Association (CBSA), representing over 100 Colorado companies.